ADARx Pharmaceuticals' IPO terms, filed September 21 and targeting a $1.74 billion valuation through 21.9 million shares priced at $15–$17, anchor current market-implied odds for its post-IPO closing market cap. AbbVie's concurrent private placement for up to $100 million (roughly 4.9% stake) and prior $335 million collaboration provide institutional validation, while the lead Phase 3 onvuzosiran candidate in hereditary angioedema benefits from recent FDA Fast Track designation. With multiple outcome buckets clustered between 12% and 24%, traders appear to price in uncertainty around final book demand, overallotment exercise, debut trading volatility, and biotech sector risk appetite ahead of the expected September 25 Nasdaq listing under ADRX. Key near-term catalysts include pricing confirmation and first-day volume.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডADARx IPO Closing Market Cap
ADARx IPO Closing Market Cap
<$1.5B 25%
$1.5B-$1.75B 24%
$2.5B-$3B 24%
$1.75B-$2B 13%
নতুন
নতুন
Sep 25, 2026
<$1.5B
25%
$1.5B-$1.75B
24%
$1.75B-$2B
13%
$2B-$2.25B
12%
$2.25B-$2.5B
12%
$2.5B-$3B
24%
$3B+
6%
No IPO before November 2026
6%
<$1.5B 25%
$1.5B-$1.75B 24%
$2.5B-$3B 24%
$1.75B-$2B 13%
নতুন
নতুন
Sep 25, 2026
<$1.5B
$0 Vol.
25%
$1.5B-$1.75B
$40 Vol.
24%
$1.75B-$2B
$0 Vol.
13%
$2B-$2.25B
$0 Vol.
12%
$2.25B-$2.5B
$0 Vol.
12%
$2.5B-$3B
$0 Vol.
24%
$3B+
$0 Vol.
6%
No IPO before November 2026
$0 Vol.
6%
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.ADARx Pharmaceuticals' IPO terms, filed September 21 and targeting a $1.74 billion valuation through 21.9 million shares priced at $15–$17, anchor current market-implied odds for its post-IPO closing market cap. AbbVie's concurrent private placement for up to $100 million (roughly 4.9% stake) and prior $335 million collaboration provide institutional validation, while the lead Phase 3 onvuzosiran candidate in hereditary angioedema benefits from recent FDA Fast Track designation. With multiple outcome buckets clustered between 12% and 24%, traders appear to price in uncertainty around final book demand, overallotment exercise, debut trading volatility, and biotech sector risk appetite ahead of the expected September 25 Nasdaq listing under ADRX. Key near-term catalysts include pricing confirmation and first-day volume.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
মার্কেট ওপেন হয়েছে: Sep 23, 2026, 6:43 PM ET
ভলিউম
$40শেষ তারিখ
Sep 25, 2026মার্কেট ওপেন হয়েছে
Sep 23, 2026, 6:43 PM ETরেজলভার
0x69c47de9d...This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.ADARx Pharmaceuticals' IPO terms, filed September 21 and targeting a $1.74 billion valuation through 21.9 million shares priced at $15–$17, anchor current market-implied odds for its post-IPO closing market cap. AbbVie's concurrent private placement for up to $100 million (roughly 4.9% stake) and prior $335 million collaboration provide institutional validation, while the lead Phase 3 onvuzosiran candidate in hereditary angioedema benefits from recent FDA Fast Track designation. With multiple outcome buckets clustered between 12% and 24%, traders appear to price in uncertainty around final book demand, overallotment exercise, debut trading volatility, and biotech sector risk appetite ahead of the expected September 25 Nasdaq listing under ADRX. Key near-term catalysts include pricing confirmation and first-day volume.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ভলিউম
$40শেষ তারিখ
Sep 25, 2026মার্কেট ওপেন হয়েছে
Sep 23, 2026, 6:43 PM ETরেজলভার
0x69c47de9d...ADARx Pharmaceuticals' IPO terms, filed September 21 and targeting a $1.74 billion valuation through 21.9 million shares priced at $15–$17, anchor current market-implied odds for its post-IPO closing market cap. AbbVie's concurrent private placement for up to $100 million (roughly 4.9% stake) and prior $335 million collaboration provide institutional validation, while the lead Phase 3 onvuzosiran candidate in hereditary angioedema benefits from recent FDA Fast Track designation. With multiple outcome buckets clustered between 12% and 24%, traders appear to price in uncertainty around final book demand, overallotment exercise, debut trading volatility, and biotech sector risk appetite ahead of the expected September 25 Nasdaq listing under ADRX. Key near-term catalysts include pricing confirmation and first-day volume.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা